The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2018 | Ibrutinib and venetoclax: a powerful combination in frontline and relapsed CLL
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Nitin Jain, MD, from the MD Anderson Cancer Center, Houston, TX, discusses his trial (NCT02756897) examining the synergistic effect of venetoclax and ibrutinib in high risk chronic lymphocytic leukemia (CLL). Current data from this study show impressive rates of minimal residual disease negativity, demonstrating the potency of this combination and the great potential of the therapy.
